NeoGenomics, Inc. (NEO)

NeoGenomics reported Q3 2025 earnings on October 28, 2025, with an EPS of $0.03 and revenue of $187.80 million. On January 12, 2026, the company announced preliminary unaudited fourth-quarter and full-year 2025 revenues, anticipating approximately $190 million for Q4 2025 and $727 million for the full year 2025. Tony Zook officially assumed the role of CEO on April 1, 2025, and Abhishek Jain is transitioning to CFO on March 2, 2026. Natera voluntarily withdrew its appeal in ongoing RaDaR patent litigation in December 2025. Over the last 52 weeks, NeoGenomics' stock has seen a low of $4.72 and a high of $14.73, with a closing price of $11.26 as of February 6, 2026.

The demand for NeoGenomics' testing services generally experiences a modest decline during summer vacation periods, year-end holidays, and other major holidays. Extreme adverse weather conditions can also lead to reduced testing volumes. The company's revenue often increases over the course of the year, with a majority generated in the latter half, partly due to the annual reset of patient deductibles. Demand from pharmaceutical and biotech customers can be unpredictable.

NeoGenomics, Inc. is a global provider of cancer-focused genetic testing solutions and information services. They offer a comprehensive menu of oncology diagnostic tests, including NGS, FISH, IHC, flow cytometry, single-gene molecular testing, and CGP. These tests guide personalized treatment strategies, identify clinical trial candidates, and advance cancer research, focusing on lung, breast, colorectal, and blood cancers. The company also provides advanced tissue-based, liquid biopsy, and heme tests and supports pharmaceutical clients in clinical trials and drug development through its Pharma Services Division.

NeoGenomics is headquartered in Fort Myers, Florida, and operates CAP accredited and CLIA certified laboratories across the United States, including locations in Florida, California, North Carolina, Texas, and Arizona. The company also maintains CAP accredited laboratories in Cambridge, United Kingdom, and serves clients throughout the United States and Europe.

NeoGenomics has a strong professional reputation as a trusted partner and leader in oncology diagnostics, emphasizing precision oncology and a commitment to patient care. The company focuses on continuous innovation, R&D, and expanding its service offerings. The voluntary withdrawal of Natera's appeal in the RaDaR patent litigation is a positive event for NeoGenomics' reputation. However, the company has faced challenges, including unprofitability with accelerating losses and consistently negative net profit margins.

Approximately 48.52% of NeoGenomics' stock is held by institutional investors, 1.20% by insiders, and 50.28% by public companies and individual investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, First Light Asset Management, LLC, Greenhouse Funds LLLP, Millennium Management Llc, State Street Corp, Deerfield Management Company, L.P., Dimensional Fund Advisors Lp, Schroder Investment Management Group, and D. E. Shaw & Co., Inc.